A tough-minded investor enters Pfizer with 7 billion RMB—will the global CEO be ousted?

The Pfizer CEO—who recently claimed, 'The best is yet to come; the company has returned to its fundamentals'—is now facing intense skepticism from shareholders and investors following a string of setbacks. Can this mysterious investor’s aggressive stakeholding propel Pfizer back to its former glory? After the global withdrawal of Oxbryta, a sickle-cell disease (SCD) drug acquired for $5.4 billion, and the failure of a $525 million oral RSV therapy, Pfizer—already enduring a streak of misfortunes—has reached a potential turning point: Starboard Value, a prominent Wall Street activist investment fund, has officially invested $1 billion (approximately 7 billion RMB) in a strategic move targeting the company. Though $1 billion may not seem like a massive sum, it is enough to prompt Pfizer’s current CEO to step in personally. According to the latest report from The Wall Street Journal, Pfizer CEO Albert Bourla and lead independent director Shantanu Narayen will meet with Starboard Value’s co-CEO Jeff Smith and Patrick Sullivan, partner overseeing its healthcare investments. Starboard Value is a hard-hitting activist investor known for stepping in when corporate operations falter or market valuations are deemed unjustifiably low. By acquiring shares, it seeks to influence management decisions and ultimately enhance shareholder value. Over its 14-year history, Starboard has maintained an almost flawless track record, delivering an average annual return of 25%. Its involvement frequently triggers executive departures—including CEOs—and major strategic overhauls at portfolio companies. Unsurprisingly, Pfizer’s stock price surged immediately upon the announcement. This development undoubtedly serves as a strong confidence booster for Pfizer investors, signaling that despite recent sharp declines in both performance and share price, the company’s long-term growth potential remains highly attractive. Interestingly, Starboard appears resolute in pursuing reform: it has already contacted Pfizer’s former CEO and former CFO, hoping they will join forces to help steer this pharmaceutical giant out of its slump. Starboard contends that under current CEO Albert Bourla, Pfizer’s once-disciplined and rational cost structure and acquisition strategy have steadily deteriorated—even collapsing altogether—and that the returns on its recent high-value acquisitions over the past two years have been disappointing. According to the Financial Times, some of Pfizer’s existing shareholders have already voiced support for Starboard’s proposal to restructure the company—and even replace its current leader, Albert Bourla. Industry dynamics shift rapidly. Three years ago, amid the pandemic-driven boom in COVID-19 products, Pfizer raked in tens of billions in revenue and solidified its status as the world’s largest pharmaceutical company. Newly appointed CEO Albert Bourla was the toast of Wall Street. Yet everyone knows what the past three years have brought to Pfizer. From lukewarm product reception and unmet financial targets, to unrecovered R&D investments and repeated failures in stubbornly pursued or newly bet-on drug development programs—Albert Bourla ultimately could not escape mounting liabilities and relentless scrutiny.

The Guardian: To alleviate funding shortages, West Ham plans to raise £30 million via a rights issue.

Live Sports News, April 6: According to The Guardian, West Ham United’s board plans to inject at least £30 million into the club via a rights issue to address financial pressures caused by the pandemic. With English football suspended nationwide due to the coronavirus crisis—and Premier League players still refusing to accept pay cuts—clubs’ concerns over falling revenues are intensifying. Several clubs have already responded to the season’s postponement by placing non-playing staff on temporary furlough. West Ham, however, is pursuing a different path: all full-time and part-time employees continue to receive full salaries. The club has agreed to launch a rights issue—inviting existing shareholders to purchase additional shares. David Sullivan, the majority shareholder holding 51% of the club’s shares, has already pledged his support. The final amount raised—whether it exceeds £30 million—depends on how many shareholders accept the offer. If some choose not to exercise their subscription rights, those shares will instead be sold elsewhere. This process is scheduled to take place in May. Although West Ham currently faces no immediate financial difficulties, that situation could change if there remains no realistic prospect of the league resuming. Clubs have warned players that failure to complete the season could cost them up to £1.137 billion collectively—partly because, should the season be abandoned, they may be forced to repay £750 million in broadcast revenue.

Braskem Discloses USD 2.25 Billion Rights Plan for Braskem Stock

3 days ago

Braskem disclosed a USD 2.25 billion rights offering proposal as part of a USD 10.9 billion restructuring negotiation. Competing plans involving equity offerings and debt conversion are being evaluated with key milestones set for late 2026.

ad-hoc-news.de

2026-04-02

Braskem (NYSE: BAK) weighs creditor protection options while reviewing capital structure

2026-04-04

Pomerantz Law Firm Investigates Braskem S.A. Over Investor Claims

2026-04-08

Braskem Reviews Creditor Options as Shareholders Weigh São Paulo Move

2026-04-08

Braskem Clarifies Capital Structure Review and Plans Shareholder Vote on Legal Domicile Change

2026-04-09

Braskem (BAK) Outlines Braskem Idesa Missed Interest Payments and Debt Talks